Sitemap - 2025 - The Drug Development Letter

"LUNAR: Full Moon or Eclipse? An exploration into tumor treating fields in lung cancer"

How to appraise the control arm in oncology trials, in 10 minutes!

"Surrogate end points in oncology: the speed-uncertainty trade-off from the patients' perspective"

The 19th St Gallen Breast Oncology Conference begins on 12 March 2025 : "Should we combine adjuvant drugs that were tested in isolation in phase 3 trials?"

The ‘Duck Test’ for Huey, Dewey and Louie: the legal case on CDK4/6 inhibitors

CDK4/6 Inhibitors and Novel Adjuvant Therapies: Using Statistics to Inform Shared Decision-Making

Vaccine Safety Research: Too Much Confounding and Spin.

The CABINET study

Excessive Drug Price Leads to Hefty Fine for Company in the Netherlands

Did pembrolizumab improve survival in patients with locally advanced cervical cancer due to poor access to post-protocol care?

Home-Grown CAR-T Cells: A Blessing or a Threat?

"The landscape of checkpoint inhibitors in oncology" – part 2! Expanding Approvals, Eligibility, and Response

One Arena Where You Can Bend the Rules to Your Advantage: Clinical Trials

Does the clinical value of a drug predict Medicare expenditures?

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts